Mesoblast Limited (NASDAQ: MESO) has recently received a number of price target changes and ratings updates:

  • 8/31/2017 – Mesoblast Limited is now covered by analysts at Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $16.00 price target on the stock.
  • 8/31/2017 – Mesoblast Limited is now covered by analysts at CIBC. They set an “outperform” rating and a $16.00 price target on the stock.
  • 8/30/2017 – Mesoblast Limited had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $20.00 price target on the stock. They wrote, “Accelerating Chronic Heart Failure (CHF). Mesoblast recently outlined its plans to seek a potential accelerated approval pathway for its MPC-150-IM product in patients with advanced cardiac heart failure. Based on the significant unmet need and serious complications of the disease, the company believes its 159-patient Phase 2b study with end-stage (Class IV) CHF patients that require left ventricular device (LVAD) assistance could support an accelerated approval. Completion of enrollment is imminent, and top-line data from the study are expected in 1Q18. The primary endpoint of the study will assess the number of times patients are able to undergo weaning off LVAD assistance. Enrolling in Advanced CHF. Mesoblast is also conducting a large 600-patient Phase 3 study in advanced (Class II/III) CHF patients that could serve as a confirmatory study and has enrolled over 400 patients so far. This study will assess recurrent, non-fatal, HF-related major adverse cardiac events between MPC-treated and sham-treated patients. Data are expected to be released in 2019. Attractive Markets. We estimate a large, multi-billion-dollar market for Mesoblast’s cell portfolio (combined royalties of ~$6 billion) when it reaches peak market penetration.””
  • 8/30/2017 – Mesoblast Limited was given a new $14.00 price target on by analysts at Maxim Group. They now have a “buy” rating on the stock. They wrote, “Mesoblast reported year-end (FYE June 30) with a net loss of $77M and ended the period with $46M in cash. The company completed a $40M raise on August 29, 2017 and currently has $84M in cash on the balance sheet.””
  • 8/23/2017 – Mesoblast Limited had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald.
  • 8/16/2017 – Mesoblast Limited was given a new $14.00 price target on by analysts at Maxim Group. They now have a “buy” rating on the stock.
  • 8/16/2017 – Mesoblast Limited was given a new $20.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock. They wrote, “Mesoblast announced publication of data from a Phase 1b/2a study with mesenchymal precursor cells (MPCs) in patients with unilateral ACL reconstruction.””
  • 7/28/2017 – Mesoblast Limited was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 7/18/2017 – Mesoblast Limited was given a new $11.00 price target on by analysts at Credit Suisse Group. They now have a “hold” rating on the stock.
  • 7/12/2017 – Mesoblast Limited was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

Mesoblast Limited (MESO) opened at 6.12 on Friday. The firm has a 50-day moving average price of $6.84 and a 200-day moving average price of $8.26. The company’s market cap is $519.49 million. Mesoblast Limited has a 12-month low of $4.01 and a 12-month high of $12.50.

Receive News & Stock Ratings for Mesoblast Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast Limited and related stocks with our FREE daily email newsletter.